Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

NCT02814565 PHASE3 COMPLETED Results posted

The purpose of this study was to assess the effect of cyclobenzaprine hydrochloride (HCl) extended release (CER) 15 mg capsule once daily in participants with muscle spasms associated with acute painful musculoskeletal conditions.

Details

Lead sponsor	Takeda
Phase	PHASE3
Status	COMPLETED
Enrolment	180
Start date	Wed Oct 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neck Pain
• Back Pain
• Spasm

Interventions

• Cyclobenzaprine HCl
• Placebo

Countries

Russia